The problem with antibiotics is that, eventually, bacteria outsmart them and become resistant. But by targeting the gene that confers such resistance, a new drug may be able to finally outwit them. Rockefeller University scientists tested the new drug, called Ceftobiprole, against some of the deadliest strains of multidrug-resistant Staphylococcus aureus (MRSA) bacteria, which are responsible for the great majority of staphylococcal infections worldwide, both in hospitals and in the community.
The research, to be published in the August 2008 issue of the journal Antimicrobial Agents and Chemotherapy, looked at how well Ceftobiprole worked against bacterial clones that had already developed resistance to other drugs. In every case, Ceftobiprole won. “It just knocked out the cells 100 percent,” says the study’s lead investigator, Alexander Tomasz, head of the Laboratory of Microbiology at Rockefeller.
Previous research had already shown that — in general — Ceftobiprole was highly effective against most clinical isolates of S. aureus. “Instead, we looked more carefully at the highly resistant cells that already occur in such clinical isolates at very low frequency — maybe in one bacterium in every 1,000,” says Tomasz. Ceftobiprole was able to kill these resistant cells.
Read more…..
The problem with antibiotics is that, eventually, bacteria outsmart them and become resistant. But by targeting the gene that confers such resistance, a new drug may be able to finally outwit them. Rockefeller University scientists tested the new drug, called Ceftobiprole, against some of the deadliest strains of multidrug-resistant Staphylococcus aureus (MRSA) bacteria, which are responsible for the great majority of staphylococcal infections worldwide, both in hospitals and in the community.
The research, to be published in the August 2008 issue of the journal Antimicrobial Agents and Chemotherapy, looked at how well Ceftobiprole worked against bacterial clones that had already developed resistance to other drugs. In every case, Ceftobiprole won. “It just knocked out the cells 100 percent,” says the study’s lead investigator, Alexander Tomasz, head of the Laboratory of Microbiology at Rockefeller.
Previous research had already shown that — in general — Ceftobiprole was highly effective against most clinical isolates of S. aureus. “Instead, we looked more carefully at the highly resistant cells that already occur in such clinical isolates at very low frequency — maybe in one bacterium in every 1,000,” says Tomasz. Ceftobiprole was able to kill these resistant cells.
Read more…..